TSX Movers: Valeant, Gold Stocks, Theratechnologies

The transcript covers Walgreens' positive outlook on its partnership with Valeant, highlighting satisfaction with Valeant's dermatology business. It also discusses the rise in gold prices as investors seek a safe haven amid global market volatility, suggesting a potential bull run. Lastly, it addresses Theratechnologies' lowered sales forecast for Egrifta, following Quebec's decision not to reimburse the drug.

What aspect of Valeant's business is Walgreens particularly satisfied with?

• Pharmaceuticals

• Dermatology

• Retail

• Technology

Why are investors turning to gold according to the transcript?

• Due to a decrease in gold prices

• Because of a new gold discovery

• To diversify their portfolios

• As a hedge against market volatility

What is the current outlook for a Fed rate hike this year?

• Very likely

• Somewhat likely

• Unlikely

• Already happened

What was the revised sales forecast for Egrifta?

• $49 million

• $37 million

• $45 million

• $50 million

What decision did Quebec make regarding Egrifta?

• To increase its price

• To place it on the reimbursable list

• Not to reimburse it

• To ban its sale